PSMA‐PET is now Medicare Benefits Schedule (MBS) funded as the primary staging imaging for newly diagnosed intermediate‐risk to high‐risk prostate cancer in Australia since 1 July 2022.12 This evidence concerns the gene FOLH1 and prostate cancer.